NCT02868645已完成不适用
Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- Periostin rate in serum
研究概览
简要总结
Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •patients with fibrous dysplasia of the bone
- •access to social security
- •informed consent
排除标准
- •no informed consent
- •pregnancy
- •patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis…)
研究组 & 干预措施
Patients with bone fibrous dysplasia
Experimental
Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
干预措施: Blood sampling (Biological)
结局指标
主要结局
Periostin rate in serum
时间窗: At inclusion
次要结局
- Periostin rate in serum in patients with Mac Cune Albright syndrome(At inclusion)
- Periostin rate in serum according to the number of fibrotic bones(At inclusion)
- Periostin rate in serum in patients with severe phenotype of the disease(At inclusion)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONEFibrous Dysplasia of BoneNCT01791842Hospices Civils de Lyon19
终止
2 期
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).Fibrodysplasia Ossificans ProgressivaNCT05039515Clementia Pharmaceuticals Inc.113
招募中
2 期
Study of Sirolimus in Idiopathic Retroperitoneal FibrosisRetroperitoneal FibrosisNCT04047576Peking University International Hospital60
已完成
不适用
A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)Fibrodysplasia Ossificans ProgressivaNCT02322255Clementia Pharmaceuticals Inc.114
已完成
2 期
An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP SubjectsFibrodysplasia Ossificans ProgressivaNCT02190747Clementia Pharmaceuticals Inc.40